Triazol-phenyl Antipyretic Derivatives Inhibit mPGES-1 mRNA Levels in LPS-Induced RAW 264.7 Macrophage Cells
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: Microsomal prostaglandin E synthase-1 (mPGES-1) catalyzes the terminal step of prostaglandin E2 (PGE2) production, which plays an important role in the regulation of febrile response. In our previous work, ligand-based pharmacophore models, built with mPGES-1 inhibitors, were employed to identify a novel series of compounds that reduce the febrile response in rats.
OBJECTIVES: The study aimed to evaluate the mechanism of action of the most active compound (1).
METHODS: For in vivo assays, rats were pretreated with the antipyretic compounds 1-8, 30 min before LPS injection. For in vitro assays, RAW 264.7 macrophage cells were incubated with the antipyretic compounds 1-8 for 1 hour before LPS stimulus. After 16 h, quantitative real-time PCR was carried out. Additionally, the PGE2 concentration in the hypothalamus was quantified by ELISA and the inhibitory effect of N-cyclopentyl-N'-[3-(3-cyclopropyl-1H-1,2,4-triazol- 5-yl)phenyl]ethanediamide (1) over human COX-2 enzymatic activity was determined with a COX Colorimetric Inhibitor Screening Assay Kit.
RESULTS: Compound 1 and CAY10526 showed comparable efficacy to reduce the febrile response when injected i.v. (compound 1: 63.10%, CAY10526: 70.20%). Moreover, compound 1 significantly reduced the mPGES-1 mRNA levels, in RAW264.7 cells, under inflammatory conditions. A chemically-similar compound (8-) also significantly reduced the mRNA levels of the gene target. On the other hand, compounds 6 and 7, which are also somewhat similar to compound 1, did not significantly impact mPGES-1 mRNA levels.
CONCLUSIONS: PGE2 concentration reduction in the hypothalamus, due to compound 1 central injection, is related to decreased mPGES-1 mRNA levels but not to COX-2 inhibition (IC50> 50 μM). Therefore, compound 1 is a promising lead for innovative antipyretic drug development.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
---|---|
Enthalten in: |
Anti-inflammatory & anti-allergy agents in medicinal chemistry - 20(2021), 3 vom: 08., Seite 271-281 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Dos Santos, Lenisa Dandara [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 06.04.2022 Date Revised 31.05.2022 published: Print Citation Status MEDLINE |
---|
doi: |
10.2174/1871523019999201208202831 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM318577569 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM318577569 | ||
003 | DE-627 | ||
005 | 20231225165635.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.2174/1871523019999201208202831 |2 doi | |
028 | 5 | 2 | |a pubmed24n1061.xml |
035 | |a (DE-627)NLM318577569 | ||
035 | |a (NLM)33292158 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Dos Santos, Lenisa Dandara |e verfasserin |4 aut | |
245 | 1 | 0 | |a Triazol-phenyl Antipyretic Derivatives Inhibit mPGES-1 mRNA Levels in LPS-Induced RAW 264.7 Macrophage Cells |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 06.04.2022 | ||
500 | |a Date Revised 31.05.2022 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
520 | |a BACKGROUND: Microsomal prostaglandin E synthase-1 (mPGES-1) catalyzes the terminal step of prostaglandin E2 (PGE2) production, which plays an important role in the regulation of febrile response. In our previous work, ligand-based pharmacophore models, built with mPGES-1 inhibitors, were employed to identify a novel series of compounds that reduce the febrile response in rats | ||
520 | |a OBJECTIVES: The study aimed to evaluate the mechanism of action of the most active compound (1) | ||
520 | |a METHODS: For in vivo assays, rats were pretreated with the antipyretic compounds 1-8, 30 min before LPS injection. For in vitro assays, RAW 264.7 macrophage cells were incubated with the antipyretic compounds 1-8 for 1 hour before LPS stimulus. After 16 h, quantitative real-time PCR was carried out. Additionally, the PGE2 concentration in the hypothalamus was quantified by ELISA and the inhibitory effect of N-cyclopentyl-N'-[3-(3-cyclopropyl-1H-1,2,4-triazol- 5-yl)phenyl]ethanediamide (1) over human COX-2 enzymatic activity was determined with a COX Colorimetric Inhibitor Screening Assay Kit | ||
520 | |a RESULTS: Compound 1 and CAY10526 showed comparable efficacy to reduce the febrile response when injected i.v. (compound 1: 63.10%, CAY10526: 70.20%). Moreover, compound 1 significantly reduced the mPGES-1 mRNA levels, in RAW264.7 cells, under inflammatory conditions. A chemically-similar compound (8-) also significantly reduced the mRNA levels of the gene target. On the other hand, compounds 6 and 7, which are also somewhat similar to compound 1, did not significantly impact mPGES-1 mRNA levels | ||
520 | |a CONCLUSIONS: PGE2 concentration reduction in the hypothalamus, due to compound 1 central injection, is related to decreased mPGES-1 mRNA levels but not to COX-2 inhibition (IC50> 50 μM). Therefore, compound 1 is a promising lead for innovative antipyretic drug development | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a COX-2 inhibition. | |
650 | 4 | |a PGE2 | |
650 | 4 | |a antipyretic | |
650 | 4 | |a expression inhibitor | |
650 | 4 | |a fever | |
650 | 4 | |a mPGES-1 | |
650 | 7 | |a Antipyretics |2 NLM | |
650 | 7 | |a Lipopolysaccharides |2 NLM | |
650 | 7 | |a RNA, Messenger |2 NLM | |
650 | 7 | |a Cyclooxygenase 2 |2 NLM | |
650 | 7 | |a EC 1.14.99.1 |2 NLM | |
650 | 7 | |a Prostaglandin-E Synthases |2 NLM | |
650 | 7 | |a EC 5.3.99.3 |2 NLM | |
650 | 7 | |a Ptges protein, mouse |2 NLM | |
650 | 7 | |a EC 5.3.99.3 |2 NLM | |
650 | 7 | |a Ptges protein, rat |2 NLM | |
650 | 7 | |a EC 5.3.99.3 |2 NLM | |
700 | 1 | |a Froes, Thamires Quadros |e verfasserin |4 aut | |
700 | 1 | |a Contin de Melo, Miriam Cristina |e verfasserin |4 aut | |
700 | 1 | |a Petto de Souza, Gloria Emília |e verfasserin |4 aut | |
700 | 1 | |a Soares, Denis de Melo |e verfasserin |4 aut | |
700 | 1 | |a Castilho, Marcelo Santos |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Anti-inflammatory & anti-allergy agents in medicinal chemistry |d 2009 |g 20(2021), 3 vom: 08., Seite 271-281 |w (DE-627)NLM194511715 |x 1875-614X |7 nnns |
773 | 1 | 8 | |g volume:20 |g year:2021 |g number:3 |g day:08 |g pages:271-281 |
856 | 4 | 0 | |u http://dx.doi.org/10.2174/1871523019999201208202831 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 20 |j 2021 |e 3 |b 08 |h 271-281 |